Skip to content

Heparin Loading Test evaluates individual differences in heparin sensitivity in critically Ill patients with venous thromboembolism

Heparin Loading Test evaluates individual differences in heparin sensitivity in critically Ill patients with venous thromboembolism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064149
Enrollment
Unknown
Registered
2022-09-27
Start date
2022-09-30
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill patients with venous thromboembolism

Interventions

heparin anticoagulant for Critically Ill Patients with Venous thromboembolism:The multiple of APTT defined as the ratio of the activated partial-thromboplastin time (aPTT) after 10mg heparin loading t

Sponsors

Dalian Municipal Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. Meet the diagnostic criteria for symptomatic deep vein thrombosis (ultrasound examination), involving the femoral vein or iliac vein; 3. Hemodynamically-stable pulmonary embolism (PE); 4. Patients and/or family members agree to participate in the clinical trial and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Use of other anticoagulant drugs for 24 h and/or recent (7 days) use of antiplatelet drugs; 2. High blood risk, such as active gastrointestinal ulcers, congenital or acquired bleeding abnormalities (platelet count < 50 x 10^9/L), a history of intracranial bleeding, moderate or severe stroke within the past 6 months, and major surgery or trauma within the last 30 days; 3. Patients with liver failure 4. Have mental illness cannot cooperate; 5. Allergic to heparin or history of thrombocytopenia caused by heparin; 6. Pregnant, recently pregnant, nursing women; 7. Contraindications to anticoagulant therapy; 8. Have participated in another drug/device study or are in the follow-up period of another drug/device study; 9. The researchers concluded that there were other conditions that were not suitable for inclusion; 10. Excluded patients were those who received UFH for less than 6 hours or without an APTT at 6 hours.

Design outcomes

Primary

MeasureTime frame
APTT;The multiple of APTT defined as the ratio of the activated partial-thromboplastin time (aPTT) after 10mg heparin loading test to the aPTT on admission.;maintenance dose of heparin for efficient anticoagulation;

Countries

China

Contacts

Public ContactShan Liu

Dalian Municipal Central Hospital

liushandl@163.com18604268682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026